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Abstract
Background: The diagnosis of growth hormone (GH) deficiency (GHD) in short children seems unquestionable
when both GH peak in stimulating tests (GHST) and IGF-I concentration are decreased. However, the discrepancies
between the results of GHST and IGF-I secretion are observed. It seems purposeful to determine the significance of
GHST and IGF-I assessment in diagnosing GHD. The relationship between GH secretion and thyroid function, as
well as GH influence on the peripheral thyroxine (T4) to triiodothyronine (T3) deiodination, mediated by IGF-I, were
identified. Thus, clear differences in thyroid function between GH-deficient and non-GH-deficient subjects should
exist.
Methods: Analysis comprised 800 children (541 boys), age 11.6 ± 3.1 years (mean ± SD), with short stature, in
whom two (2) standard GHST (with clonidine and with glucagon) were performed and IGF-I, free T4 (FT4), free T3
(FT3) and TSH serum concentrations were assessed. The patients were qualified to the following groups: GHD -
decreased GH peak in GHST and IGF-I SDS (n = 81), ISS - normal GH peak and IGF-I SDS (n = 347), low GH -
normal IGF-I SDS, and decreased GH peak (n = 212), low IGF - decreased IGF-I SDS, and normal GH peak (n = 160).
The relationships among the results of particular tests were evaluated.
Results: In the groups with decreased IGF-I concentrations (GHD Group and low IGF Group), the more severe
deficit of height was observed, together with higher TSH and FT4 but lower FT3 levels than in groups with normal
IGF-I concentrations (ISS Group and low GH Group), independently of the results of GHST. TSH, FT4 and FT3
concentrations were - respectively - similar in two groups with decreased IGF-I secretion, as well as in two groups
with normal IGF-I levels. Significant correlations were found between patients’ height SDS and IGF-I SDS, between
FT3 and IGF-I SDS (positive), and between FT4 and IGF-I SDS (negative), with no correlation between GH peak and
any of the parameters analyzed.
Conclusion: The assessment of thyroid function in children with short stature provides the evidence that
measurement of IGF-I concentration may be a procedure reliable at least to the some degree in diagnosing GHD
as the results of GHST.
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The growth hormone (GH) secretion is routinely evalu-
ated in children with short stature, on the ground of the
results of GH stimulating tests (GHST) with different
pharmacological stimuli [1,2]. Insulin-like growth factor-
I (IGF-I) is the main peripheral mediator of GH activity.
The assessment of IGF-I secretion is an important diag-
nostic tool, as its synthesis is GH-dependent, whereas
serum concentration - on the contrary to GH levels -
relatively stable [3]. The diagnosis of GH deficiency
(GHD) seems unquestionable when both GH peak in
GHST and IGF-I concentration are decreased. Consis-
tently, GHD may be excluded in the patients, in whom
both GH and IGF-I secretion are normal. In such cases,
the diagnosis of idiopathic short stature (ISS) seems to
be the most adequate after careful exclusion of other
possible causes of short stature (including genetically-
determined syndromes, chronic diseases, malnutrition,
etc.). However, in clinical practice, the discrepancies
either between the results of GHST and IGF-I secretion
or between the results of particular GHST are - quite
frequently - observed. According to current recommen-
dations, two (2) different GHST are required in every
case and their results should be interpreted together
[1,2]. The problem of the poor reproducibility of GHST
was raised - among others - by Rosenfeld et al. [4] and
Price et al. [5]. Next, the possibility of obtaining normal
results of GHST in children, previously diagnosed as
GH-deficient (i.e.i nc h i l d r e nw i t hs u b n o r m a lG H
response to pharmacological stimulation in past) was
documented in several studies [5-8]. The relationships
between GH secretion, more presently - between the
results of GHST and IGF-I levels were assessed in
numerous studies. Unfortunately, their results are inco-
herent, either confirming [9-12] or denying [13-16] the
correlation between GH peak in GHST and IGF-I secre-
tion. In 2005, Cianfarani et al. [3] stated that IGF-I
concentrations were reliable indicators of daily GH
secretion, due to their GH dependency and relative sta-
bility in circulation. Similar were the results of much
earlier observations of Rosenfeld et al. [17] and Shalet
et al. [18]. In one of our previous studies [19], the stabi-
lity of IGF-I concentration was also proved, despite
divergent results of the repeated GHST.
Taking into account all the doubts concerning diag-
nosing GHD in children, it seems purposeful to search
for other indices that could be helpful in the evaluation
of GH secretory status. Particularly, further studies on
determining the significance of both GHST and IGF-I
assessment among the diagnostic procedures seem
promising.
The relationships between GH secretion and thyroid
function, as well as GH influence on the peripheral thyr-
oxine (T4) to triiodothyronine (T3) deiodination were
identified during the observations of patients with GHD,
either untreated or subjected to GH therapy. The first
studies, carried out about 30 years ago, revealed an
increase of T4 to T3 conversion, leading to an increase
of extrathyroidal T3 concentration, together with a
decrease of T4 concentration during GH administration
[20,21]. These observations were also confirmed by the
results of subsequent studies. In 1989, Jørgensen et al.
[22] confirmed the observation that GH replacement
induced an enhancement of T4 to T3 deiodination. In
1994, the same research group[ 2 3 ]d e m o n s t r a t e dt h a t
in the adult patients with GHD the levels of T3
remained decreased, even in the course of T4 substitu-
tion, while normalizing during GH replacement therapy
(parallel to the decrease of TSH levels). The key role of
IGF-I in stimulating the process of T4 to T3 deiodina-
tion was also suggested by Jørgensen et al. [24].
On the other hand, the influence of thyroid function
disorders on GH secretion, as well as on IGF system,
was also described. Thus, it was shown that hypothyr-
oidism (HypoT) - even in its subclinical form - might
affect IGF-I secretion [25]. Moreover, it was previously
supposed that the effects of thyroid hormone on IGF-I
secretion could be independent from GH mediation
[26,27]. In particular, a significant decrease of IGF-I and
IGF binding protein-3 (IGFBP-3) concentrations was
documented in the patients with HypoT, both in adults
[28] and in children [29]. Furthermore, it was shown
that T4 replacement therapy improved the previously
decreased GH and IGF-I secretion, however, with no
complete recovery [30].
As it was mentioned before, a decrease of T4 to T3
deiodination, leading to the decrease of T3 concentra-
tion with reference to T4 level, should be observed in
GH-deficient patients. Ceratinly, the individual variances
of the thyroid function or/and in the activity of periph-
eral deiodinases must also be taken into account. Never-
theless, it seems that in the study including large groups
of patients, the clear differences between GH-deficient
and non-GH-deficient subjects should be identified.
The aim of current study was to compare the selected
indices of thyroid function in children with short sta-
ture, diagnosed towards GHD, with reference to both
the results of GHST and IGF-I secretion. In fact, we
expected to reveal the differences between the groups
with either normal or subnormal results of GHST and/
or between those with either normal or decreased IGF-I
levels, as since such observations could contribute to
optimizing the assessment of GH secretory status in
children with short stature.
Methods
The retrospective analysis comprised 800 children
(541 boys, 259 girls), age 11.6 ± 3.1 years (mean ± SD),
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rd centile
for age and sex), diagnosed at our Department (2001-
2010). All the children underwent the following diagnos-
tic procedures:
-p a t i e n t s ’ height was measured on admission to the
hospital and was expressed as height SDS (hSDS) for
age and sex for Polish children [31]; taking into
account the normal distribution of heights in the
population of children, an exact value -1.88 was
assumed as hSDS for 3
rd centile;
- two (2) GHST were performed in children
admitted to the hospital, remaining fasting, in the
morning hours. For stimulation, clonidine in a dose
of 0.15 mg/m
2 p.o.( 1
st test), and glucagon in a dose
of 30 μg/kg i.m., not exceeding 1 mg (2
nd test) were
used. Blood samples for GH estimation were col-
lected every 30 min from 0 to 120 min in the tests
with clonidine and at 0, 90, 120, 150 and 180 min in
the test with glucagon;
- serum IGF-I, free T4 (FT4), free T3 (FT3) and TSH
concentrations were measured in single blood sam-
ples, obtained in 0 min of 1
st stimulating test, just
before clonidine administration.
The main assumption of the study was to include the
patients either with ISS or with isolated non-acquired
GHD only. In order to avoid the possible influence of
disorders of thyroid function on GH and/or IGF-I secre-
tion and action, only the children with values of TSH,
FT4,a n dF T 3 concentrations within the reference range
were included into the analysis. The exclusion criteria
encompassed any chronic diseases, other hormonal defi-
ciencies, acquired GHD, Turner syndrome in girls, other
genetically determined syndromes, malnutrition and
obesity (assessed as body mass index either below or
over the reference range respectively for age and sex
[31]).
The concentrations of GH were measured by the two-
site chemiluminescent enzyme immunometric assay
(hGH IMMULITE, DPC) for the quantitative measure-
ment of human GH, calibrated to WHO IRP 80/505
standard. The analytical sensitivity of the assay was up
to 0.01 ng/ml, the calibration range up to 40 ng/ml, the
sensitivity of 0.01 ng/ml, the intra-assay coefficient of
variation (CV) of 5.3-6.5% and the inter-assay CV of
5.5-6.2%. The cut-off value for normal and subnormal
GH peak in response to stimulation was 10.0 ng/ml
according to current recommendations [1,2].
Serum IGF-I concentrations were assessed by Immu-
lite, DPC assays; WHO NIBSC 1
st IRR 87/518 standard
was applied, with analytical sensitivity 20 ng/ml, calibra-
tion range up to 1600 ng/ml, intra-assay CV - 3.1-4.3%
and inter-assay CV - 5.8-8.4%. For comparison among
children of different age and sex, IGF-I concentrations
were expressed as IGF-I SDS, according to DPC refer-
ence data. As it was stated before, IGF-I values higher
than -1.0 SD reflected a normal GH secretion [3]. Thus,
we decided to select just that threshold value as the cut-
off level for normal and decreased IGF-I secretion in
our study.
Serum TSH, FT4 and FT3 concentrations were mea-
sured by the electroimmunochemiluminescent method
(ECLIA), Roche, Elecsys
®Systems 1010/2010/modular
analytics E170. For TSH, the analytical sensitivity was
0.005 μIU/ml, range - up to 100 μIU/ml, intra-assay
coefficient of variance (CV) - 1.5-8.6%, accuracy - 1.1-
3.0%. The analytical range for FT4 was 0.023-7.77 ng/ml,
intra-assay CV - 1.4-2.9%, accuracy - 2.7-6.6%. For FT3,
the analytical range was 0.26-32.55 pg/ml, intra-assay
CV - 3.7-9.5%, accuracy - 3.8-11.2%. For the assessment
of FT3/FT4 molar ratio, the concentrations of FT4 and
FT3 were expressed as molar ones.
According to the results of GHST (normal or subnor-
mal) and to IGF-I secretion (normal or decreased), the
patients were qualified to the following groups:
- GHD - the patients with decreased both GH peak
in GHST and IGF-I SDS (n = 81);
- ISS - the patients with normal both the results of
GHST and IGF-I SDS (n = 347);
- low GH - the patients with normal IGF-I SDS,
despite decreased GH peak in GHST (n = 212);
- low IGF - the patients with decreased IGF-I SDS,
despite normal GH peak in GHST (n = 160).
The analysis of the relationships between the compo-
nents of somatotrophic axis (the results of GHST, IGF-I
concentration) and the components of the pituitary -
thyroid axis (TSH, FT4 and FT3 concentrations) were
assessed. Statistical analysis included Kruskal-Wallis’
nonparametric test for independent samples, as well as
the assessment of correlations between patient’sh e i g h t
and the results of particular hormonal tests.
Results
The deficit of height (expressed as hSDS for age and
sex) proved to be the most expressed in low IGF Group
(i.e. in the patients with low IGF-I and normal GH peak
in GHST), being significantly lower than that in both
ISS Group (p < 0.001) and low GH Group (p < 0.001),
as well as than that in GHD Group (p = 0.031). Inter-
estingly, both the mean value and the distribution of
hSDS values in ISS Group and in low GH Group (i.e.
in the groups of patients with normal IGF-I secretion)
were similar, despite completely different results of
GHST in them. Moreover, hSDS values in these groups
were also higher than those in the groups with
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(also independently of the results of GHST).
The levels of TSH were also very similar in ISS Group
and in low GH Group, being - at the same time - lower
than both in GHD Group (the differences insignificant -
NS) and than in low IGF Group (NS and p = 0.032,
respectively), while the difference between GHD Group
and low IGF Group was insignificant.
Moreover, FT4 concentrations turned out to be very
similar in ISS Group and in low GH Group, being also
significantly lower than both in GHD Group (p < 0.001
and p = 0.002, respectively) and in low IGF Group (p <
0.001 for both pairs compared).
Interestingly, there was no significant difference in FT3
concentrations between ISS Group and low GH Group,
while in these two groups, FT3 concentrations were sig-
nificantly higher than those in both GHD Group (p =
0.012 and p = 0.010, respectively) and low IGF Group
(p = 0.001 for both pairs compared). The difference
between GHD Group and low IGF Group did not
reach the border of significance.
Finally, FT3/FT4 molar ratio was similar in ISS Group
and low GH Group, being - in these two groups - sig-
nificantly higher (p < 0.0001) than those in GHD Group
and in low IGF Group, while the difference between the
latter two groups was also insignificant. More detailed
data, are presented Table 1 and Figures 1, 2, 3, 4 and 5.
Summing up, in groups of patients with decreased
IGF-I concentrations (i.e.i nGHD Group and in low
IGF Group) ,t h em o r es e v e r ed e f i c i to fh e i g h tw a s
observed, together with higher TSH and FT4 levels but
lower FT3 concentrations than those in groups with
normal IGF-I concentrations (i.e.i nISS Group and in
low GH Group). All the assessed parameters of thyroid
function presented similar in the two groups with
decreased IGF-I secretion (i.e. GHD Group and low
IGF Group). There were no important differences
between groups with normal IGF-I levels (i.e. ISS
Group and low GH Group).
As a matter of fact, there were no strong correlations
between the assessed indices of thyroid function (TSH,
free thyroid hormones) and the parameters of somato-
trophic axis (GH peak in GHST, IGF-I). However, a sig-
nificant, positive correlation was found between patients’
hSDS and IGF-I SDS (r = 0.25, p < 0.05), while there
was no correlation between hSDS and GH peak in
GHST (r = 0.03, NS). A positive correlation was also
observed between IGF-I SDS and FT3 concentration
(r = 0.24, p < 0.05), together with a negative one
between IGF-I SDS and FT4 (r = -0.20, p < 0.05) and
with no correlation between IGF-I SDS and TSH level
(r = -0.06, NS). Thus, the observed correlations seem to
be independent from TSH level, while an increase of
IGF-I concentration may be related to the increase of
FT3 and decrease of FT4. Moreover, there was no corre-
lation between GH peak and any of the parameters ana-
lyzed. Detailed data are shown in Table 2.
Discussion
In our study, groups with decreased IGF-I levels (i.e.,
GHD Group and low IGF-I Group) presented with the
relatively higher TSH and FT4 but lower FT3 concentra-
tions than those with normal IGF-I secretion, indepen-
dently from either subnormal or normal GH peak in
G H S T .I ts h o u l db er e c a l l e dt h a tG H Dl e a d st ot h e
decrease of peripheral T4 to T3 deiodination [20-23].
Thus, the observed lower FT3 concentrations in both
Table 1 Patients’ height and thyroid function in particular groups of children
Group GHD low IGF-I low GH ISS
max GH [ng/ml]
IGF-I SDS
< 10 ng/ml
< -1.0
≥10 ng/ml
< -1.0
< 10 ng/ml
≥-1.0
≥10 ng/ml
≥-1.0
hSDS for age and sex -2.31 ± 0.88
a,b -2.50 ± 0.81
a,c,d -2.10 ± 0.66
c -2.08 ± 0.67
b,d
TSH [mIU/l] 2.33 ± 1.27 2.40 ± 1.01
e 2.17 ± 0.75
e 2.17 ± 1.08
FT4 [ng/dl] 1.25 ± 0.23
f,g 1.28 ± 0.23
h,i 1.16 ± 0.20
f,h 1.17 ± 0.24
g,i
FT3 [pg/ml] 4.03 ± 0.83
j,k 4.09 ± 0.80
l,m 4.44 ± 0.80
j,l 4.35 ± 0.74
k,m
FT3/FT4 [molar ratio] 0.40 ± 0.11
n,o 0.39 ± 0.10
p,r 0.48 ± 0.14
n,p 0.46 ± 0.12
o,r
Significant differences: a,b - p < 0.05; c,d - p < 0.001; e-p < 0.05; f-p < 0.005; g,h,i,j - p < 0.01; k,l,m - p < 0.001; n,o,p,r - p < 0.0001.
Figure 1 Patients’ height (expressed as hSDS) in particular groups
of children. Significant differences: a,b - p < 0.05; c,d - p < 0.001.
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levels in them seem to correspond with GHD in these
patients. Moreover, the very similar FT4,F T 3 and TSH
concentrations in both groups with normal IGF-I levels
(i.e., in ISS Group and low GH Group), independently
from either normal or subnormal results of GHST,
should be stressed. We are convinced that these obser-
vations speak against the disorders of thyroid function
related to GHD in both groups with normal IGF-I secre-
tion, especially since we certainly do not expect such
disorders in patients with ISS.
According to previous suggestions that IGF-I may be a
mediator of GH action on stimulating peripheral T4
deiodination [24], the results of current study seem
quite reliable. The quoted observation allows to explain
the results obtained in GHD Group, ISS Group, and -
to some extent - in low IGF Group. In fact, in the latter
group, either decreased GH sensitivity or other comple-
tely overlooked diseases, present in most of children,
should be assumed as the only possible cause of
decreased IGF-I secretion. Taking into account both the
relatively low incidence of GH insensitivity and the
exclusion criteria, such possibility seems, however,
poorly justified. Next, the results, obtained in low GH
Group do not seem to be explained by anything - except
for the falsely positive (i.e., falsely decreased) GH peaks
in both performed GHST. In these patients, not only
IGF-I concentrations are normal but also they corre-
spond to the similar thyroid status as we observed in
ISS Group.
As it was mentioned before, the discrepancies between
the results of GHST and IGF-I secretion were reported
in numerous studies [9-12], being explained either by
the individual differences in GH sensitivity [32] or by
the lack of concordance between GH secretion under
physiological conditions and the results of GHST
[33-35]. The conclusions, derived from these observa-
tions were also non-consistent. For instance, Rasat et al.
[36] proposed IGF-I assessment as a screening proce-
dure in diagnosing GHD. Similar was the statement of
Figure 2 TSH secretion in particular groups of patients.
Significant difference: a - p < 0.05.
Figure 3 FT4 secretion in particular groups of patients.
Significant differences: a - p < 0.005; b,c,d - p < 0.01.
Figure 4 FT3 concentrations in particular groups of patients.
Significant differences: a - p < 0.01; b,c,d - p < 0.001.
Figure 5 Molar ratio FT3/FT4 in particular groups of patients.
Significant differences: a,b,c,d - p < 0.0001.
Table 2 Correlations between the indices of thyroid
function and the components of somatotrophic axis
hSDS GH peak
[ng/ml]
IGF-I SDS TSH
[mIU/l]
FT4
[ng/dl]
FT3
[pg/ml]
hSDS 0.03 0.25* -0.05 0.05 0.13*
GH peak
[ng/ml]
0.03 0.12* 0.01 0.12* 0.00
IGF-ISDS 0.25* 0.12* -0.06 -0.20* 0.24*
TSH [mIU/l] -0.05 0.01 -0.06 0.12* 0.10*
FT4 [ng/dl] 0.05 0.12* -0.20* 0.12* 0.03
FT3 [pg/ml] 0.13* 0.00 0.24* 0.10* 0.03
Correlations marked * are significant (p < 0.05).
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dence that it may be impossible to predict the results of
GHST on the ground of IGF-I concentration
[9,12-14,16,40-42]. It seems very important to ade-
quately answer the question, which (if any) of these pro-
cedures is the most reliable one in GHD diagnosing.
According to current recommendations [1,2], GHST are
the main tools for the assessment of GH secretion.
However, some other options were also proposed. Thus,
Badaru and Wilson [43] stated that IGF-I assessment
had of no less importance than the results of GHST.
Similarly, Loche at al. [7] suggested that the diagnosis of
GHD should not exclusively be based on the results of
GHST. In 2009, Lemaire et al. [44] proposed the assess-
ment of growth rate and IGF-I concentration as the
screening procedures in children suspected for GHD, in
order to reduce the necessity of subjecting the patients
to GHST. The results of our previous studies [19,45]
also speak for the significance of IGF-I assessment in
GHD diagnosing, thus bringing into question the cred-
ibility of GHST.
Another issue, however not analyzed in the current
study, is an assessment of spontaneous GH secretion.
Although - up to now - this procedure has not been
recommended for clinical practice according to interna-
tional guidelines [2], the data exist that GH administra-
tion to short children with decreased stimulated but
normal spontaneous GH secretion is not associated
with an increase of final height [46]. It seems that not
only decreased spontaneous GH secretion should be
taken into account in short children with low IGF-I
concentrations (leading to the diagnosis of neurosecre-
tory dysfunction) but also normal spontaneous GH
secretion must be considered in the patients with nor-
mal IGF-I levels, despite decreased GH peak in GHST.
It should also be taken into account that the relatively
high incidence of falsely positive results of the two (2)
GHST, performed in an individual patient was revealed
in one of our previous studies [47]. As in Poland the
assessment of spontaneous GH secretion after falling
asleep was introduced as an obligatory procedure
(screening) in diagnosing GHD in children, our research
team intends to assess prospectively both IGF-I secre-
tion and thyroid function with respect to nocturnal GH
secretion.
Conclusion
It seems that the assessment of thyroid function, while
diagnosing GHD in children with short stature, provides
the evidence that IGF-I concentration may be no less
reliable indicator of GH action than the results of
GHST, at least in children suspected for idiopathic, iso-
lated GHD and after exclusion of other causes of
impaired IGF-I secretion.
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